Literature DB >> 12754408

Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit.

Kye-Im Jeon1, Mi-Sun Byun, Dae-Myung Jue.   

Abstract

Antirheumatic gold compounds have been shown to inhibit NF-kappaB activation by blocking IkappaB kinase (IKK) activity. To examine the possible inhibitory mechanism of gold compounds, we expressed wild type and mutant forms of IKKalpha and beta subunits in COS-7 cells and determined the effect of gold on the activity of these enzymes both in vivo and in vitro. Substitution of Cys-179 of IKKbeta with alanine (C179A) rendered the enzyme to become resistant to inhibition by a gold compound auranofin, however, similar protective effect was not observed with an equivalent level of IKKalpha (C178A) mutant expressed in the cells. Auranofin inhibited constitutively active IKKalpha and beta and variants; IKKalpha (S176E, S180E) or IKKbeta (S177E, S181E), suggesting that gold directly cause inhibition of activated enzyme. The different inhibitory effect of auranofin on IKKalpha (C178A) and IKKbeta (C179A) mutants indicates that gold could inhibit the two subunits of IKK in a different mode, and the inhibition of NF-kappaB and IKK activation induced by inflammatory signals in gold-treated cells appears through its interaction with Cys-179 of IKKbeta.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754408     DOI: 10.1038/emm.2003.9

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  42 in total

1.  Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis.

Authors:  Michael B Harbut; Catherine Vilchèze; Xiaozhou Luo; Mary E Hensler; Hui Guo; Baiyuan Yang; Arnab K Chatterjee; Victor Nizet; William R Jacobs; Peter G Schultz; Feng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

2.  MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis.

Authors:  Yi Wang; Xiaoou Shan; Gaozhi Chen; Lili Jiang; Zhe Wang; Qilu Fang; Xing Liu; Jingying Wang; Yali Zhang; Wencan Wu; Guang Liang
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

3.  Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta.

Authors:  Niki L Reynaert; Albert van der Vliet; Amy S Guala; Toby McGovern; Milena Hristova; Cristen Pantano; Nicholas H Heintz; John Heim; Ye-Shih Ho; Dwight E Matthews; Emiel F M Wouters; Yvonne M W Janssen-Heininger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

4.  The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells.

Authors:  Seon-Joo Park; In-Sook Kim
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

Review 5.  Phytochemicals as potential IKK-β inhibitor for the treatment of cardiovascular diseases in plant preservation: terpenoids, alkaloids, and quinones.

Authors:  Fang Hua; Lingli Shi; Peng Zhou
Journal:  Inflammopharmacology       Date:  2019-09-05       Impact factor: 4.473

6.  Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4.

Authors:  Hyung S Youn; Joo Y Lee; Shin I Saitoh; Kensuke Miyake; Daniel H Hwang
Journal:  Biochem Biophys Res Commun       Date:  2006-09-28       Impact factor: 3.575

7.  Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.

Authors:  Michelle Kiebala; Jolanta Skalska; Carla Casulo; Paul S Brookes; Derick R Peterson; Shannon P Hilchey; Yun Dai; Steven Grant; Sanjay B Maggirwar; Steven H Bernstein
Journal:  Exp Hematol       Date:  2014-10-22       Impact factor: 3.084

8.  Glutaredoxin regulates autocrine and paracrine proinflammatory responses in retinal glial (muller) cells.

Authors:  Melissa D Shelton; Anne M Distler; Timothy S Kern; John J Mieyal
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

Review 9.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

10.  High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors.

Authors:  Samuel A Siles; Anand Srinivasan; Christopher G Pierce; José L Lopez-Ribot; Anand K Ramasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.